VitaNova Life Sciences (VNOV) Liabilities and Shareholders Equity (2017 - 2026)

VitaNova Life Sciences' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 74.99% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $9.1 million (up 83.9% YoY) and the FY2025 annual result came in at $2.3 million, up 89.15% from the prior year.
• Liabilities and Shareholders Equity was $2.3 million for Q1 2026 at VitaNova Life Sciences, down from $2.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 million in Q4 2025 and bottomed at $8728.0 in Q2 2023.
• A 5-year average of $1.0 million and a median of $1.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 73.97% — and 2024, when it soared 13567.03%.
• VitaNova Life Sciences' Liabilities and Shareholders Equity stood at $35190.0 in 2022, then tumbled by 75.2% to $8728.0 in 2023, then surged by 14322.69% to $1.3 million in 2024, then jumped by 85.59% to $2.3 million in 2025, then fell by 1.05% to $2.3 million in 2026.
• Business Quant data shows VNOV's Liabilities and Shareholders Equity at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.2 million in Q3 2025.